AB0157 The diagnostic performance of a candidate multi-biomarker score in early rheumatoid arthritis. (23rd January 2014)

• Record Type: Journal Article
• Authors: Novikov, A.; Alexandrova, E. N.; Gerasimov, A. N.; Karateev, D. E.; Luchihina, E. L.; Nasonov, E. L.
• Is Part Of: Annals of the rheumatic diseases. Volume 72:Supplement 3(2013)
• Page Start: A833
• Page End: A833
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-eular.2480
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: In the early phase of rheumatoid arthritis (RA) the patients do not yet fulfill the criteria for disease 1 . To meet the need for improved diagnostic tests and algorithms, various serum biomarkers are being assessed for the improved diagnosis of RA. However, only rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) have gained wide acceptance 2 . Objectives: A multi-biomarker score (MB) are powerful emerging tests that have the potential to answer significant clinical diagnostics problems by integrating multiple proteomic markers 3 . The aim of this study was to evaluate the performance of a candidate multi-biomarker score in diagnosis of early RA (MBERA). Methods: We studied 102 patients (pts) with early RA (with<6 months disease duration) (23 man, 79 woman, median age 51, 41-62years), 27 pts with systemic lupus erythematosus (SLE), 15 pts with Sjogren's syndrome, 25 pts with ankylosing spondylitis, 24 pts with osteoarthritis, 20 pts with OVERLAP, 9 pts with gout, 22 pts with psoriatic arthritis, 168 pts with undifferentiated arthritis and 297 healthy individuals. 4 antibodies (IgM RF, IgA RF, anti-CCP, AMCV), 3 inflammation markers (ESR, CRP, calprotectin), markers of bone (sRANKL) and cartilage (COMP) metabolism, 27 cytokines (IL-1β, -1ra, -2, -4, -5, -6, -7, -8, -9, -10, -12, -13, -15, -17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF) serum concentrationswere measured. Analysis of consistency and confidence as biomarkers of early RA was carried out by multivariate logistic regression. Results: The MBERA score was calculated based on the concentrations of 6 biomarkers (anti-CCP, CRP, IL-6, IFN-γ, GM-CSF, IP-10). The MDERA demonstrate a superior performance (AUC 0, 98; sensitivity 94%; specificity 81%; LR+ 4, 9; LR- 0, 1) versus RF (AUC 0, 8; sensitivity 67%; specificity 79%; LR+ 3, 2; LR- 0, 4) and anti-CCP (AUC 0, 7; sensitivity 59%; specificity 87%; LR+ 4, 5; LR- 0, 4) to diagnosis early RA. Conclusions: Diagnostic performance of MBERA is superior versus IgM RF and anti-CCP. After accurate validation, this test could be used in clinical laboratory practice. References: A. Willemze, R.E.M. Toes, T.W.J. Huizinga, L.A. Trouw. New biomarkers in rheumatoid arthritis. Neth J Med. 2012 Nov;70(9):392-9. P. Taylor, J. Gartemann, J. Hsieh, J. Creeden. A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis. Autoimmune Diseases Volume 2011, Article ID 815038, doi:10.4061/2011/815038. http://www.cap.org/apps/docs/committees/technology/ivdmia.pdf Disclosure of Interest: None Declared